HLA-C and neoplasm: As a follow-up, such systems can be expanded toother (tumor-specific) antigens, such as NY-ESO-I or neo-antigens.We expect that differences due to topological effects will be moreprevalent, due to the lower avidity of the peptide–MHC complexfor the T cell receptor, which will further enhance the importanceof ligand density and morphology.